Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
SRRK Stock Chart & Stats
$42.93
-$0.51(-1.26%)
At close: 4:00 PM EST
$42.93
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$22.71 - $48.28
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.86M
Market Cap
$4.49B
Enterprise Value$3.98B
Total Cash (Recent Filing)$369.63M
Total Debt (Recent Filing)$110.08M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 10, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding102,007,454
10 Day Avg. Volume1,432,534
30 Day Avg. Volume1,857,213
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.71
Price to Sales (P/S)0.00
P/FCF Ratio-21.46
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.44K
Enterprise Value/Ebitda-11.31
Forecast
1Y Price Target
$47.88Price Target Upside11.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentApitegromab is the first myostatin-targeting therapy to show a statistically significant benefit in motor function in a pivotal trial.
Market PotentialThere is a significant market opportunity for apitegromab in SMA, with risk-adjusted peak sales modeled at $2bn in 2037.
Regulatory Approval ProgressSRRK held their Type A meeting with FDA to discuss the re-submission of their BLA for apitegromab in spinal muscular atrophy, highlighting constructive dialogue with FDA and now anticipating re-submission, approval, and US launch in 2026.
Bears Say
Investor SentimentScholar Rock's shares are expected to remain volatile and very sensitive to any additional headlines or disclosures in the near term.
Manufacturing ChallengesThe Catalent Indiana facility, acquired by Novo Nordisk, received an Official Action Indicated (OAI) classification, which is seen as a net negative for near-term approval prospects for Scholar Rock's apitegromab.
Regulatory DelaysThe FDA issued a Complete Response Letter (CRL) for apitegromab in spinal muscular atrophy due to unresolved compliance observations at Catalent's Indiana facility.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $22.71 and its highest was $48.28 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $4.49B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Mar 10, 2026 which is in 79 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Nov 14, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.842 by -$0.058.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.89.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 102,007,454 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.842. Following the earnings report the stock price went up 24.41%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.88 (11.53% Upside)
$47.88 (11.53% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $27.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.07%
12-Months-Change
Fundamentals
Return on Equity
-218.04%
Trailing 12-Months
Asset Growth
129.84%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of optimism due to strong financial management, significant trial results for apitegromab, and strategic preparation for commercial launch. However, these positives are tempered by regulatory delays and uncertainties surrounding the approval timeline due to third-party facility compliance issues.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$47.88
▲(11.53% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
Currently, No data available
---